Biohaven

BHVN · NYSE · United States

Share price · BHVN

$12.90-0.67 (-4.94%) 3M

close as of 2026-11-18 · 24h delayed · vol 2.3M (0.7x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when BHVN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 22 Oct 2026+25.0%
  2. 17 Sep 2026+15.6%
  3. 10 Sep 2026-14.7%
  4. 26 Aug 2026+17.9%
  5. 22 Jun 2026+14.2%
  6. 17 Jun 2026+12.7%

    Nothing announced by BHVN that day or the session before.

  7. 28 May 2026-9.3%
  8. 27 May 2026+12.1%
  9. 11 May 2026-7.9%

    Nothing announced by BHVN that day or the session before.

  10. 17 Apr 2026+9.7%

Share of unusual movement by asset

For each asset, the share of BHVN's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Opakalim
events and moves
86%
Troriluzole
events and moves
6shown from 8 days
taldefgrobep alfa
events and moves
2shown from 8 days
BHV-1400
events and moves
1shown from 8 days
BHV-2100
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—28%
Other company news (earnings, financing, releases naming no asset)—14%
Sessions with no dated event—52%

Assets

(7 total)
7Total Assets
0Approved
3Phase 3 / Filed
4Phase 1–2 / Early
8Diseases
Quick filter:
Showing 7 of 7 assets
Target & Modality
Phase 3
Gd-IgA1 (galactose-deficient IgA1)Biologic (subtype unspecified)
Chronic Kidney Disease
Phase 3
Activin/myostatin type II receptorAntibody-derived scaffold
ObesitySpinal Muscular Atrophy
Phase 3
Glutamate transporters (EAAT)Small molecule
Spinocerebellar Ataxia
Phase 2/3
TYK2/JAK1Small molecule
Parkinson's Disease
Phase 2/3
Kv7 potassium channelSmall molecule
Epilepsy
Focal Onset Seizures
Phase 2
TRPM3
Migraine
PBI-100No recent activity
Phase 1
TrkASmall molecule
Psoriasis

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
OpakalimPhase 2Focal Epilepsy
Est. primary completion 2026-12 · NCT06443463 · CT.gov ↗
What to watch
OpakalimPhase 2/3Focal Epilepsy
Est. primary completion 2026-12 · NCT06132893 · CT.gov ↗
What to watch
2027 (1)
August 2027 (1)
BHV-8000Phase 2/3Parkinson Disease
Est. primary completion 2027-08 · NCT06976268 · CT.gov ↗
What to watch
2028 (1)
September 2028 (1)
BHV-1400Phase 3IgA Nephropathy
Est. primary completion 2028-09 · NCT07642050 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(10)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

22 October 2026Filing acceptedTroriluzoleFDA accepts the troriluzole (Vyglxia) NDA resubmission for SCA
US, FDA · Biohaven · Source ↗
4 September 2026Clinical holdOpakalimFDA places partial clinical hold on new enrollment in opakalim (BHV-7000) program
US, FDA · FDA · Source ↗
26 August 2026Licensing dealOpakalimBiohaven signs exclusive worldwide licence of opakalim to SK Biopharmaceuticals (not yet closed)
Biohaven Ltd. · Source ↗
26 May 2026Topline resultOpakalimOpakalim Phase 2/3 study in idiopathic generalized epilepsy (NCT06425159): median time to second GTC seizure 141 vs 47 days
Biohaven Ltd. · Source ↗
4 November 2025Complete response lettertroriluzole (VYGLXIA)FDA issues complete response letter for VYGLXIA (troriluzole) NDA in spinocerebellar ataxia
US, FDA · Biohaven · Source ↗
3 March 2025Topline resultOpakalimBHV-7000 bipolar mania Phase 2/3 (NCT06419582) missed its primary endpoint
Biohaven Ltd. · Source ↗
11 February 2025Filing acceptedTroriluzoleFDA accepts troriluzole NDA for SCA
US, FDA · Source ↗
11 February 2025Priority reviewTroriluzoleFDA grants Priority Review to troriluzole NDA
US, FDA · Source ↗
16 December 2024Filing submittedTroriluzoleTroriluzole NDA submitted for SCA
US, FDA · Source ↗
25 November 2024Topline resulttaldefgrobep alfaPhase 3 RESILIENT (NCT05337553) misses its primary endpoint at Week 48
Biohaven · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$102M$99M+ $65M short-term inv.$129M-$107M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$101M$241M+ $30M short-term inv.$137M-$85M operating cash flowreport ↗
2026-Q1—$104M$277M+ $75M short-term inv.$131M-$150M operating cash flowreport ↗
2025-Q3—$141M$188M+ $75M short-term inv.$173M-$146M operating cash flowreport ↗
2025-Q2—$184M$169M+ $239M short-term inv.$198M-$168M operating cash flowreport ↗
2025-Q1—$188M$103M+ $224M short-term inv.$222M-$165M operating cash flowreport ↗
2024-Q3—$158M$88M+ $294M short-term inv.$160M-$141M operating cash flowreport ↗
2024-Q2—$315M$242M+ $198M short-term inv.$320M-$168M operating cash flowreport ↗
2024-Q1—$156M$187M+ $101M short-term inv.$180M-$103M operating cash flowreport ↗
2023-Q3—$96M$126M+ $129M short-term inv.$103M-$95M operating cash flowreport ↗
2023-Q2—$79M$202M+ $188M short-term inv.$90M-$44M operating cash flowreport ↗
2023-Q1—$63M$191M+ $263M short-term inv.$70M-$78M operating cash flowreport ↗
2022-Q3—$53M$51M$69M-$96M operating cash flowreport ↗
2022-Q2—$177M$24M$203M-$68M operating cash flowreport ↗
2022-Q1—$70M$41M$97M-$59M operating cash flowreport ↗
2021-Q3—$47M$363M$54Mreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$635M$233M+ $89M short-term inv.$185M-$609M operating cash flowreport ↗

Biohaven reported no revenue disclosure for FY2025, with R&D spend of $635.07M, down 20.2% YoY from $795.87M. Cash and equivalents were $232.78M, and the company reported a net loss of $738.82M, with a stated quarterly net burn of $738.82M; total cash, cash equivalents, marketable securities and restricted cash approximated $322.0M as of December 31, 2025.

The company is prioritizing three late-stage programs: extracellular protein degraders for immunology, Kv7 modulation for epilepsy, and myostatin-activin targeting for obesity. BHV-1300 showed IgG reductions up to 87% and is planned for a pivotal Graves’ disease study in 2H 2026; BHV-1400 achieved early biomarker and clinical responses in IgAN, with a pivotal study expected to initiate in 1Q 2026; opakalim’s open-label extension showed 50% or greater seizure frequency reductions in most participants completing six months, with pivotal topline results expected in 2H 2026; and taldefgrobep alfa’s Phase 2 obesity trial topline is expected in 2H 2026. Biohaven also initiated a 4Q 2025 restructuring expected to cut annual direct R&D spend by approximately 60%, and subsequently raised $178.9M in net proceeds from a common share sale.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$796M$103M+ $387M short-term inv.$212M-$582M operating cash flowreport ↗
2023-FY—$373M$252M+ $133M short-term inv.$102M-$332M operating cash flowreport ↗
2022-FY—$437M$243M+ $260M short-term inv.$143M-$298M operating cash flowreport ↗
2021-FY—$181M$77M+ $0 short-term inv.$53M-$146M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-09-15Gentile Kimberly · SVP, Clinical OperationsAward / grant (derivative)1,000——Form 4
2026-04-28GREGORY JULIA P · directorAward / grant (derivative)68,693——Form 4
2026-04-28HUGIN ROBERT J · directorAward / grant (derivative)68,693——Form 4
2026-04-28CHILDS JOHN W · directorAward / grant (derivative)68,693——Form 4
2026-04-28Antonijevic Irina · directorAward / grant (derivative)68,693——Form 4
2026-04-28Heffernan Michael Thomas · directorAward / grant (derivative)68,693——Form 4
2026-04-28Bailey Gregory · directorAward / grant (derivative)68,693——Form 4
2026-04-28Mehta Kishan · directorAward / grant (derivative)68,693——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 273 reporting institutions held 143.6M shares ($1.2B, 95.4% of shares outstanding).

#InstitutionSharesValue
1JANUS HENDERSON GROUP PLC17,534,612$148.2M
2BlackRock, Inc.11,222,407$94.9M
3SUVRETTA CAPITAL MANAGEMENT, LLC10,286,937$87.0M
4STIFEL FINANCIAL CORP9,940,885$84.1M
5STATE STREET CORP6,618,803$56.0M
6INFINITUM ASSET MANAGEMENT, LLC6,250,000$52.9M
7TCG Crossover Management, LLC4,631,317$39.2M
8STEMPOINT CAPITAL LP3,188,982$27.0M
9Royalty Pharma Sub-Manager, LLC2,936,507$24.8M
10D. E. Shaw & Co., Inc.2,847,193$24.1M
11GEODE CAPITAL MANAGEMENT, LLC2,767,763$23.4M
12GOLDMAN SACHS GROUP INC2,513,181$21.3M
13Balyasny Asset Management L.P.2,445,416$20.7M
14FMR LLC2,359,047$20.0M
15VANGUARD PORTFOLIO MANAGEMENT LLC2,279,275$19.3M